| URL | https://www.biopharma-reporter.com/Article/2021/11 |
| Source | Bio Pharma Reporter |
| Date Published | 11/25/2021 |
| Author Name | Jane Byrne |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | SK Investment |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2020 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | Korea, Republic of |
| City reshored to: | Philadelphia |
| State(s) reshored to: | PA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | cell and gene therapy |